Form 4: Climb Bio Director Reports Stock Option Grant

Climb Bio, Inc. director Breanna Maurine Celebi reported the acquisition of a stock option for 70,284 shares.

Summary

• Breanna Maurine Celebi, a Director at Climb Bio, Inc., has reported the acquisition of a stock option.
• The stock option grants the right to purchase 70,284 shares of common stock at an exercise price of $13.36 per share.
• The option has a vesting commencement date of June 29, 2026, and will vest in equal monthly installments over three years.
• The option is exercisable until June 29, 2036.
• The reporting person disclaims beneficial ownership of the option and underlying shares, as they are held for the benefit of RA Capital Management, L.P. entities and a separately managed account.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on a standard stock option grant to a director and does not contain new financial performance data or strategic shifts.

Positives

• Director Celebi has been granted a significant stock option, indicating potential future equity participation.
• The stock option is exercisable for a substantial number of shares (70,284), aligning the director's interests with long-term company performance.
• The vesting schedule over three years encourages continued service and commitment to the company's growth.

Negatives

• The reporting person disclaims beneficial ownership, suggesting the option is not for personal gain but rather for the benefit of investment funds managed by RA Capital Management.
• The exercise price of $13.36 per share means the option will only be profitable if the stock price rises above this level.

Risks

• The value of the stock option is contingent on the future performance of Climb Bio, Inc.'s stock price.
• The vesting of the option is subject to the reporting person's continued service, meaning any departure before full vesting would result in forfeiture of unvested options.

Future Outlook

The stock option grant suggests a long-term outlook for Climb Bio, Inc., with the director's compensation tied to future stock performance. The vesting schedule indicates expectations of continued growth and value creation over the next three years.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology sector to incentivize leadership and align their interests with shareholders, especially during early-stage development or growth phases.

Related Party Transactions

• The reporting person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account.
• The reporting person is obligated to transfer any proceeds from exercising the option to RA Capital Management, L.P. to offset advisory fees owed by these entities.

Stakeholder Impact

• Shareholders: The option grant aligns director compensation with potential future stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: While not directly impacted, the alignment of director incentives with company success can indirectly benefit employees through improved company performance.
• RA Capital Management Entities: These entities are the ultimate beneficiaries of the stock option, with proceeds offsetting advisory fees.

Next Steps

• The stock option will vest monthly from June 29, 2026, over three years, subject to continued service.
• The reporting person is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, L.P. entities.

Key Dates

Keywords

Form 4, Stock Option, Beneficial Ownership, Climb Bio, Inc., Director, RA Capital Management, Equity, Vesting